GLPwatch
Papers (9189)
Page 134 of 154, ranked by citation count.
- Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study.
- Discontinuation of Tirzepatide and Semaglutide Prior to Gastric Sleeve Surgery: Clinical Considerations and Guidelines.
- Tirzepatide vs. Semaglutide for Obesity Treatment.
- New Drug Capsule: Tirzepatide.
- New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
- [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)].
- Validity and analysis of the Diabetes Injection Device Preference Questionnaire (DID-PQ).
- Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.
- Enhancing GLP-1 expression via IVT mRNA and fusion protein technology for diabetes therapy.
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
- Is it time to REWIND the cardiorenal clock in diabetes?
- Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.
- Inclusion of drugs on the World Health Organization's Essential Medicines List: A game-changer for obesity?
- Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta-Analysis.
- Older Adults' Views on Insurance Coverage for Weight Management Medications.
- Safety Choice Drivers of the Coming Treatment Options for Non-Cirrhotic Metabolic Steatohepatitis.
- Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study.
- The impact of GLP-1 agonists on sleep disorders: spotlight on sleep apnea.
- Optimizing GLP-1 therapies for obesity and diabetes management.
- Comment on "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients".
- Bezlotoxumab.
- Pneumoperitoneum by subcutaneous injections of GLP-1 analogues. A case report.
- A Clinical Overview of Once-weekly Glucagon-like Peptide-1 Receptor Agonists.
- How to reset metabolic setpoint in obesity management.
- Diabetes with GLP-1R polymorphism (rs3765467) accompanied by myotonic dystrophy: A case of myotonic dystrophy with p.R131Q polymorphism at the glucagon-like peptide-1 receptor (rs3765467) resulting in marked effects of its agonist, dulaglutide.
- Metabolic Consequences of Glucagon-Like Peptide-1 Receptor Agonist Shortage: Deterioration of Glycemic Control in Type 2 Diabetes.
- Preoperative weight loss by noninvasive approach in patients with obesity scheduled for bariatric and metabolic surgery: an update narrative review of indications and results available until 2024.
- Advancing Diabetes Management and Glycemic Control While Exploring CagriSema's Impact on Obesity Management.
- A Systemic Review of Pharmacological Management of Pediatric Obesity.
- Obesity treatment as a bridge to solid organ transplantation: A comparison of bariatric surgery to medical therapy.
- Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
- Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children.
- Choosing injectable therapy: The metabolic fulcrum.
- The revolution of the anti-diabetic drugs in cardiology.
- Editorial: Incretin agonists in the treatment of obesity.
- [Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?]
- [Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review].
- Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.
- Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management.
- Gateways to clinical trials.
- Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis.
- GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS.
- Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment.
- [Benefits of telematic monitoring for weight loss in overweight and obese patients in times of confinement].
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder: Current Evidence and Future Directions.
- Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.
- [Cardiovascular disease in diabetic patients: risk factors, clinical history and prevention].
- Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.
- Novel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
- Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
- Drug-induced lesions of the oesophageal mucosa.
- Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes.
- Retatrutide.
- Targeting cardiometabolic risk in type 1 diabetes through incretin physiology.
- Glucagon-like peptide-1 receptor agonists and obesity paradox in heart failure with preserved ejection fraction: a systematic review.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.
- EHR Data Suggest Tirzepatide Outdoes Semaglutide for Weight Loss.
- Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.